Optimi Health Corp. (OPTH)
NASDAQ: OPTH · Real-Time Price · USD
4.490
-0.150 (-3.23%)
At close: Oct 2, 2026, 4:00 PM EDT
4.510
+0.020 (0.45%)
After-hours: Oct 2, 2026, 7:30 PM EDT
Optimi Health Revenue
Optimi Health had revenue of 140.20K CAD in the quarter ending June 30, 2026, a decrease of -28.61%. This brings the company's revenue in the last twelve months to 175.67K, down -67.95% year-over-year. In the fiscal year ending September 30, 2025, Optimi Health had annual revenue of 426.30K with 9.35% growth.
Revenue (ttm)
175.67K CAD
Revenue Growth
-67.95%
P/S Ratio
207.81
Revenue / Employee
n/a
Employees
n/a
Market Cap
25.71M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 426.30K | 36.45K | 9.35% |
| Sep 30, 2024 | 389.85K | 208.76K | 115.28% |
| Sep 30, 2023 | 181.09K | 100.37K | 124.35% |
| Sep 30, 2022 | 80.72K | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Rockwell Medical | 69.39M |
| Aytu BioPharma | 57.57M |
| Biofrontera | 46.18M |
| SCYNEXIS | 19.22M |
| Zhengye Biotechnology Holding | 16.64M |
| China Pharma Holdings | 3.91M |
| TherapeuticsMD | 3.27M |
| Incannex Healthcare | 12.00K |
OPTH News
- 4 days ago - Optimi Health Appoints Melanie Pump to Board of Directors - GlobeNewsWire
- 10 days ago - Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply - GlobeNewsWire
- 11 days ago - Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer - Financial Post
- 11 days ago - Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer - GlobeNewsWire
- 16 days ago - Optimi Health Plans Phase 3 Trial Of MDMA-Assisted Therapy For PTSD - Nasdaq
- 17 days ago - Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder - Financial Post
- 17 days ago - Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder - GlobeNewsWire
- 22 days ago - Optimi Health Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts